Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Estonia

European Innovation Council · Running

NANOWOUND Antibacterial wound dressing based on advanced nanotechnology to improve the efficiency of wound care

Coordinator
Nanordica Medical Ou, Estonia
Runs
1 April 2023 to 31 March 2026
Status
Running
EU funding
€2.4m
Total cost
€3.4m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190199469

What the project is doing

In the project's own words, from its summary on CORDIS.

Infected wounds are a major cause of limb amputations among patients with chronic diseases like diabetes. 10mln amputations occur annually causing €100bln additional healthcare costs. During COVID-19 pandemic the number of amputations rose 10 fold due to low efficacy of current solutions. Nanordica develops an advanced Antibacterial Wound Dressing (AWD) to prevent and treat wound infections. We have demonstrated that our AWD removes bacterial infection 8x better than current best.

Our value propositions are high efficacy and low cost. Global antibacterial wound dressing market is projected to reach €4.2bln in 2026 at CAGR 5.7%. Our business model is B2B using distributors to reach our customers, i.e. hospitals. We have a priority for intellectual property and initiated a pilot clinical trial at the largest Estonian hospital. Our mission is to bring AWD to the market to improve the outcome of wound infections, lower healthcare costs and help hundreds of millions of patients.

Topics

Who is involved

OrganisationCityCountryRole
Nanordica Medical OuTallinnEstoniaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI